Raymond Lam

VCH Clinical Title(s)

Medical Director, Mood Disorders Centre, Djavad Mowafaghian Centre for Brain Health

Research Focus

Brain and Nerves Mental Health and Behaviour Mood Disorders

Degrees / Designations

MD, FRCPC

Contact Info

raymond-w-lam-a63535a/

Biography

Dr. Raymond Lam is a professor in the Department of Psychiatry at the University of British Columbia, director of the Mood Disorders Centre at the Djavad Mowafaghian Centre for Brain Health and the BC Leadership Chair in Depression Research.

Dr. Lam's research examines clinical and neurobiological factors in seasonal, treatment-resistant and workplace depression; biological and therapeutic effects of light therapy; clinical trials; clinical guidelines; digital health technologies; and global mental health. He is a lead investigator for the Canadian Biomarker Integration Network in Depression (CAN-BIND), executive chair of the Asia-Pacific Economic Cooperation (APEC) Digital Hub for Mental Health, and past executive chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). His research is funded by many agencies and sponsors, including the Canadian Institutes of Health Research and Michael Smith Foundation for Health Research.

Research Studies

Depression

News and Awards

Publications

The Journal of clinical psychiatry -
The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhu M, Hong RH, Yang T, Yang X, Wang X, Liu J, Murphy JK, Michalak EE, Wang Z, Yatham LN, Chen J, Lam RW
International journal for equity in health -
Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review.
Murphy JK, Khan A, Sun Q, Minas H, Hatcher S, Ng CH, Withers M, Greenshaw A, Michalak EE, Chakraborty PA, Sandanasamy KS, Ibrahim N, Ravindran A, Chen J, Nguyen VC, Lam RW
JAMA psychiatry -
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Lam RW, Levitt AJ, Levitan RD, Michalak EE, Cheung AH, Morehouse R, Ramasubbu R, Yatham LN, Tam EM
Canadian journal of psychiatry. Revue canadienne de psychiatrie -
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R,
BMC psychiatry -
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Geraci J, Giacobbe P, Feilotter HE, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, Liotti M, MacQueen GM, McAndrews MP, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC, Ravindran AV, Salomons TV, Soares CN, Strother SC, Turecki G, Vaccarino AL, Vila-Rodriguez F, Kennedy SH,

Raymond Lam

Biography

Research Studies

A Feasibility Study of Adherence to Light Therapy for Maintenance Treatment of Major Depressive Disorder

Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Wellness Monitoring for Major Depressive Disorder

Canadian Biomarker Integration Network for Depression Study (CAN-BIND-1)

News and Awards

Innovation and Translational Research Awards 2021 Recipients

Ask an expert: Grey winter days are bringing me down. How can I beat the winter blues?

The trillion dollar global burden of depression

Patient finds light in darkness through depression research participation

Mobile app helps track and manage symptoms of depression, anxiety

Biomarkers of depression offer hope for personalized treatment

Publications

The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review.

Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.

Are you a researcher?